Infectious Disease
-
SCORPIO-PEP Trial: Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts
The SCORPIO-PEP trial evaluated ensitrelvir as postexposure prophylaxis for household contacts of Covid-19 patients and showed a significant reduction in symptomatic Covid-19 by day 10. Introduction The SCORPIO-PEP trial evaluated whether ensitrelvir, an oral antiviral agent, could prevent Covid-19 in people recently exposed to SARS-CoV-2 within their household. Household exposure remains one of the highest-risk